Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma

Pediatr Hematol Oncol. 2010 Mar;27(2):138-49. doi: 10.3109/08880010903447367.


The authors report a case of a 13-year-old female with recurrent Burkitt lymphoma who was heavily pretreated with chemotherapy. During chemotherapy for relapse, she developed serious aspergillus infection of the palate and sinuses. Despite 10 microg/kg of filgrastim for 5 days, peripheral blood CD34(+) cells remained <or=1/microL. Hematopoietic progenitor cells were subsequently successfully mobilized with a combination of AMD3100 and filgrastim without tumor or fungus contamination. After transplantation, the patient achieved complete engraftment without exacerbation of fungal infection. This is the first case report of a pediatric patient with relapsed Burkitt lymphoma with mobilization of hematopoietic progenitor cells by AMD3100 without any adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzylamines
  • Burkitt Lymphoma / diagnosis
  • Burkitt Lymphoma / pathology
  • Burkitt Lymphoma / therapy*
  • Cyclams
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Hematopoietic Stem Cell Mobilization*
  • Heterocyclic Compounds / therapeutic use*
  • Humans
  • Peripheral Blood Stem Cell Transplantation*
  • Recombinant Proteins
  • Recurrence
  • Treatment Outcome


  • Benzylamines
  • Cyclams
  • Heterocyclic Compounds
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim
  • plerixafor